Atorvastatin indications and usage: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
==Indications and Usage== | ==Indications and Usage== | ||
LIPITOR is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to: | LIPITOR is an inhibitor of [[HMG-CoA reductase]] (statin) indicated as an adjunct therapy to diet to: | ||
* Reduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors. | * Reduce the risk of [[MI]], [[stroke]], revascularization procedures, and [[angina]] in patients without CHD, but with multiple risk factors. | ||
* Reduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors. | * Reduce the risk of [[MI]] and [[stroke]] in patients with type 2 [[diabetes]] without CHD, but with multiple risk factors. | ||
* Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in patients with CHD. | * Reduce the risk of non-fatal [[MI]], fatal and non-fatal [[stroke]], revascularization procedures, hospitalization for CHF, and [[angina]] in patients with CHD. | ||
* Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. | * Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed [[dyslipidemia]]. | ||
* Reduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia. | * Reduce elevated TG in patients with [[hypertriglyceridemia]] and primary dysbetalipoproteinemia. | ||
* Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH). | * Reduce total-C and LDL-C in patients with homozygous familial [[hypercholesterolemia]] (HoFH). | ||
* Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy . | * Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial [[hypercholesterolemia]] after failing an adequate trial of diet therapy . | ||
===Limitations of Use=== | ===Limitations of Use=== | ||
LIPITOR has not been studied in Fredrickson Types I and V | LIPITOR has not been studied in Fredrickson Types I and V [[dyslipidemia]]s. | ||
Revision as of 14:58, 30 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
Indications and Usage
LIPITOR is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to:
- Reduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors.
- Reduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors.
- Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in patients with CHD.
- Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia.
- Reduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia.
- Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH).
- Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy .
Limitations of Use
LIPITOR has not been studied in Fredrickson Types I and V dyslipidemias.